ALFA Finder
18:52 IST
BSE
Earnings Call
MPS Earnings Call Transcript: Key Takeaways
H1 FY27 was a record: revenue rose 17.8% to ₹448.5 Cr and EBITDA 39% to ₹154 Cr at a 34.3% margin, with zero debt. Q2 margin was also 34.3%.
MPS Ltd
- Share price
- ₹2,263.40
- Market cap
- ₹3,872 Cr
- Revenue (annual)
- ₹768.4 Cr
- Net profit (annual)
- ₹173.2 Cr
- P/E (TTM)
- 20.9×Sector 46.8×
- Promoter holding
- 68.34%+0.00% QoQ
- FII holding
- 1.49%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Earnings Call 7Management Change 6Other Announcement 5Merger & Restructuring 4Annual General Meeting 4Financial Results 3Business Update 3Board Meeting Date 2Acquisition 2Price Movement Clarification 1Board Meeting Outcome 1Annual Report 1
Time
7 announcements with these filters
22:14 IST
BSE
Earnings Call
MPS Investor Presentation: Key Takeaways
Q2 FY27 revenue +15.35% YoY to INR 22,429 Lakhs; EBITDA +27.39%, record 34.34% margin. H1 EBITDA INR 154 Cr; zero debt, cash INR 16,323 Lakhs.
19:35 IST
NSE
Earnings Call
MPS Earnings Call Transcript: Key Takeaways
MPS delivers record Q1 FY27 results, leveraging high operating leverage and AI integration to drive EBITDA growth significantly faster than revenue.
22:18 IST
BSE
Earnings Call
MPS Investor Presentation: Key Takeaways
MPS reports record Q1 FY27 results with 20.38% revenue growth and 53.03% EBITDA surge, driven by the Unbound Medicine acquisition and AI-enabled workflows.
19:03 IST
BSE
Earnings Call
MPS Earnings Call: Key Takeaways
MPS Limited reports FY26 as its most profitable year, driven by AI-led knowledge solutions and the acquisition of Unbound Medicine.
18:58 IST
BSE
Earnings Call
MPS Earnings Call: Key Takeaways
MPS closed FY26 with record profitability, driven by its transformation into an AI-first knowledge solutions provider and the successful integration of Unbound Medicine.
00:06 IST
NSE
Earnings Call
MPS Earnings Call: Key Takeaways
MPS Limited reported record FY26 EPS of ₹102.11 (+16.3% YoY) with consolidated EBITDA of ₹236 Cr (30.7% margin), driven by an AI-first strategy and the Unbound Medicine acquisition.